Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

House dust mite allergy immunotherapy tablet - Stallergenes Greer plc

Drug Profile

House dust mite allergy immunotherapy tablet - Stallergenes Greer plc

Alternative Names: Actair; House dust mite allergy immunotherapy - Stallergenes Greer plc; House dust mite SLIT; House dust mite sublingual immunotherapy; Oralair Mites; S-524101; STAGR 320; STG 320

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Stallergenes SA
  • Developer Shionogi; Stallergenes Greer plc
  • Class Allergens; Allergy immunotherapies; Antiallergics
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Allergic asthma; Perennial allergic rhinitis

Most Recent Events

  • 02 Jun 2021 Stallergenes Greer announces intention to launch house dust mite allergy immunotherapy tablet for Perennial allergic rhinitis in selected European countries
  • 31 May 2021 Registered for Perennial allergic rhinitis in European Union (Sublingual)
  • 20 Nov 2018 Stallergenes announces intention to submit BLA to the US FDA as well as for additional marketing authorizations in European and international markets for Perennial allergic rhinitis
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top